RTP Mobile Logo
Meet The Professor: Immunotherapy and Novel Agents in Gynecologic Cancers (Webinar Video Proceedings)
Released March 2021

Featuring perspectives from Dr Michael J Birrer. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    These activities are intended for gynecologic oncologists, medical oncologists, gynecologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gynecologic cancers.

    LEARNING OBJECTIVES

    • Describe the biologic rationale for, published research data with, and ongoing evaluation of the use of immune checkpoint inhibitors in the management of ovarian cancer, endometrial cancer (EC) and cervical cancer (CC).
    • Appraise the clinical research findings supporting the FDA approval of anti-PD-1 monotherapy for PD-L1-positive, progressive metastatic CC, and counsel appropriate patients about the risks and potential benefits of this treatment approach.
    • Review available data with anti-PD-1/PD-L1 antibodies for microsatellite instability-high (MSI-H) and microsatellite stable recurrent EC, and identify patients who may be eligible for this strategy as part of a clinical research study or outside of a protocol setting.
    • Assess the recent FDA approval of pembrolizumab in combination with lenvatinib for patients with advanced EC that is not MSI-H/mismatch repair deficient who experience disease progression after prior systemic therapy but are not candidates for curative surgery or radiation therapy, and optimally integrate this novel regimen into current clinical management algorithms.
    • Recognize the incidence of tissue factor expression in patients with CC and other gynecologic cancers, and consider emerging pivotal research findings with and the potential role of tisotumab vedotin for recurrent CC.
    • Recall the design of ongoing clinical trials evaluating novel agents and strategies for gynecologic cancers, and counsel appropriate patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPGynOnc21/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Presenting Faculty Member

    Michael J Birrer, MD, PhD
    Vice Chancellor, UAMS
    Director, Winthrop P Rockefeller Cancer Institute
    Director, Cancer Service Line
    University of Arkansas for Medical Sciences
    Little Rock, Arkansas

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company.

    Contributing Investigator

    Brian M Slomovitz, MD, MS
    Professor, Department of Obstetrics and Gynecology
    Florida International University
    Miami, Florida

    Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Myriad Genetic Laboratories Inc; Consulting Agreement: GOG Foundation Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Eisai Inc, Merck, Seagen Inc and Tesaro, A GSK Company.

    Release date: March 2021
    Expiration date: March 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):